Actively Recruiting
A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes
Led by Eli Lilly and Company · Updated on 2026-03-11
124
Participants Needed
1
Research Sites
80 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate how well LY4057996 is tolerated and what side effects may occur in healthy participants and participants with Type 1 and Type 2 Diabetes. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4057996 gets into the bloodstream and how long it takes the body to eliminate it. The study will last 11 weeks for Part A1-A2, 4 weeks for A3-A5, 6 weeks for Part B and 7 weeks for Part C, all approximations, excluding a screening period.
CONDITIONS
Official Title
A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- For healthy participants: must be overtly healthy based on medical evaluation including history, physical exam, lab tests, and heart screening
- For Type 2 Diabetes participants: diagnosed more than 1 year ago
- For Type 2 Diabetes participants in Cohort 5: on basal insulin therapy (insulin glargine, detemir, or degludec) over 10 units per day for at least 6 months
- HbA1c between 6.5% and 9.5% for Type 2 Diabetes participants at screening
- For Type 1 Diabetes participants: have the disease for at least 1 year with fasting C-peptide ≤0.20 nmol/L or non-fasting C-peptide ≤0.30 nmol/L
- HbA1c between 6% and 8.5% for Type 1 Diabetes participants at screening
- Blood pressure less than 140/90 mmHg for healthy participants or less than 150/90 mmHg for diabetes participants
- Pulse rate less than 90 bpm (supine)
- No hypoglycemia unawareness for all diabetes participants
You will not qualify if you...
- More than 1 emergency room visit or hospitalization for poor glucose control in the 6 months before screening
- Any severe hypoglycemia episodes or hypoglycemia unawareness in the 6 months before screening
- Significant history of cardiovascular disease
- Gastrointestinal conditions like gastroparesis or history of gastric surgery
- Acute or chronic hepatitis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Profil Institut für Stoffwechselforschung
Neuss, Germany, 41460
Actively Recruiting
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
P
Physicians interested in becoming principal investigators please contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
BASIC_SCIENCE
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here